Excelitas announces breakthrough performance results with its solid state silicon photomultiplier (SiPM) technology

Pittcon 2011, WALTHAM, USA: Excelitas Technologies, a global technology leader focused on delivering innovative, customized optoelectronics to OEMs seeking high-performance technology solutions, announced that it has achieved record, world-class performance results for high photon detection efficiency (PDE) and low dark counts in the development and commercialization of its solid state silicon photomultipliers (SiPMs) technology.

SiPMs are an important element in Excelitas’ low light level detection (L3D) suite of technologies and products targeting the medical and analytical market space.

The results have been published and presented at the “CERN Industry-Academia Matching Event on SiPM and Related Technologies,” which took place in Geneva, Switzerland on February 16-17, 2011. The event brought together 120 experts active in cutting-edge photon detection work from both industry and academia.

In 2009, the company entered into an exclusive agreement with Max Planck Innovation, the technology transfer organization of the Max Planck Society, for the licensing of its ultra-fast, low cross-talk SiPM technology. Silicon photomultipliers offer very high PDE, ultra-short response time, and extremely low power consumption, making them ideal for a variety of low light level applications such as fluorescence and molecular imaging.

“Excelitas is very pleased to be able to present these breakthrough technology results on its solid state SiPM technology. We are delighted to be able to disseminate state-of-the-art results and are gratified with the strong interest in testing and evaluating Excelitas’ SiPM technology in real experimental situations,” according to Michael Ersoni, senior vice president and general manager of Excelitas’ global detection business.

“Excelitas is firmly committed to the rapid growth of its low light level detection portfolio for meeting high-volume requirements in the most advanced of life sciences, clinical diagnostics, and analytical instrument applications,” Ersoni added.